Novavax (NVAX) EBIAT: 2009-2025
Historic EBIAT for Novavax (NVAX) over the last 17 years, with Sep 2025 value amounting to -$202.4 million.
- Novavax's EBIAT fell 66.84% to -$202.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.7 million, marking a year-over-year increase of 219.97%. This contributed to the annual value of -$187.5 million for FY2024, which is 65.60% up from last year.
- According to the latest figures from Q3 2025, Novavax's EBIAT is -$202.4 million, which was down 290.01% from $106.5 million recorded in Q2 2025.
- In the past 5 years, Novavax's EBIAT ranged from a high of $518.6 million in Q1 2025 and a low of -$846.3 million during Q4 2021.
- In the last 3 years, Novavax's EBIAT had a median value of -$121.3 million in 2024 and averaged -$28.2 million.
- Per our database at Business Quant, Novavax's EBIAT slumped by 1,910.83% in 2021 and then skyrocketed by 451.51% in 2025.
- Novavax's EBIAT (Quarterly) stood at -$846.3 million in 2021, then soared by 78.46% to -$182.2 million in 2022, then increased by 2.12% to -$178.4 million in 2023, then soared by 54.58% to -$81.0 million in 2024, then plummeted by 66.84% to -$202.4 million in 2025.
- Its EBIAT was -$202.4 million in Q3 2025, compared to $106.5 million in Q2 2025 and $518.6 million in Q1 2025.